Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

What evidence do we need for biomarker qualification?

Leptak C, Menetski JP, Wagner JA, Aubrecht J, Brady L, Brumfield M, Chin WW, Hoffmann S, Kelloff G, Lavezzari G, Ranganathan R, Sauer JM, Sistare FD, Zabka T, Wholley D.

Sci Transl Med. 2017 Nov 22;9(417). pii: eaal4599. doi: 10.1126/scitranslmed.aal4599. Review.

PMID:
29167393
2.

Advancing Value Assessment in the United States: A Multistakeholder Perspective.

Sorenson C, Lavezzari G, Daniel G, Burkholder R, Boutin M, Pezalla E, Sanders G, McClellan M.

Value Health. 2017 Feb;20(2):299-307. doi: 10.1016/j.jval.2016.11.030.

3.

International Experiences in Quantitative Benefit-Risk Analysis to Support Regulatory Decisions.

Reed SD, Lavezzari G.

Value Health. 2016 Sep - Oct;19(6):727-729. doi: 10.1016/j.jval.2016.06.004. No abstract available.

4.

Industry perspectives on biomarker qualification.

Lavezzari G, Womack AW.

Clin Pharmacol Ther. 2016 Feb;99(2):208-13. doi: 10.1002/cpt.264. Epub 2015 Oct 22. Review.

5.

Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation.

Winner JG, Carhart JM, Altar CA, Goldfarb S, Allen JD, Lavezzari G, Parsons KK, Marshak AG, Garavaglia S, Dechairo BM.

Curr Med Res Opin. 2015;31(9):1633-43. doi: 10.1185/03007995.2015.1063483. Epub 2015 Jul 23.

PMID:
26086890
6.

Monitoring phosphoproteomic response to targeted kinase inhibitors using reverse-phase protein microarrays.

Lavezzari G, Lackner MR.

Methods Mol Biol. 2012;795:203-15. doi: 10.1007/978-1-61779-337-0_14.

PMID:
21960225
7.

Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.

Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G.

Hepatology. 2009 Oct;50(4):1140-51. doi: 10.1002/hep.23118.

PMID:
19711426
8.

Corequirement of PICK1 binding and PKC phosphorylation for stable surface expression of the metabotropic glutamate receptor mGluR7.

Suh YH, Pelkey KA, Lavezzari G, Roche PA, Huganir RL, McBain CJ, Roche KW.

Neuron. 2008 Jun 12;58(5):736-48. doi: 10.1016/j.neuron.2008.03.028.

9.

mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082.

Pelkey KA, Yuan X, Lavezzari G, Roche KW, McBain CJ.

Neuropharmacology. 2007 Jan;52(1):108-17. Epub 2006 Aug 17.

PMID:
16914173
10.

Constitutive endocytosis of the metabotropic glutamate receptor mGluR7 is clathrin-independent.

Lavezzari G, Roche KW.

Neuropharmacology. 2007 Jan;52(1):100-7. Epub 2006 Aug 7.

PMID:
16890965
11.

mGluR7 is a metaplastic switch controlling bidirectional plasticity of feedforward inhibition.

Pelkey KA, Lavezzari G, Racca C, Roche KW, McBain CJ.

Neuron. 2005 Apr 7;46(1):89-102.

12.

Subunit-specific regulation of NMDA receptor endocytosis.

Lavezzari G, McCallum J, Dewey CM, Roche KW.

J Neurosci. 2004 Jul 14;24(28):6383-91.

13.

Supplemental Content

Loading ...
Support Center